Concert Pharmaceuticals, Inc. (NASDAQ:CNCE – Get Rating) – Investment analysts at Jefferies Financial Group issued their FY2027 earnings per share estimates for Concert Pharmaceuticals in a research report issued on Thursday, January 19th. Jefferies Financial Group analyst M. Raycroft expects that the biotechnology company will post earnings of $0.39 per share for the year. Jefferies Financial Group has a “Hold” rating on the stock. The consensus estimate for Concert Pharmaceuticals’ current full-year earnings is ($2.70) per share.
Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) last released its quarterly earnings results on Monday, November 7th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.33 million.
Concert Pharmaceuticals Trading Down 0.1 %
NASDAQ:CNCE opened at $8.28 on Monday. The stock has a market cap of $396.93 million, a P/E ratio of -2.58 and a beta of 0.30. The stock’s 50-day moving average is $5.48 and its 200-day moving average is $5.83. Concert Pharmaceuticals has a 1-year low of $2.57 and a 1-year high of $8.34.
Insiders Place Their Bets
In other Concert Pharmaceuticals news, CEO Roger D. Tung sold 9,240 shares of the stock in a transaction that occurred on Friday, January 6th. The stock was sold at an average price of $7.24, for a total transaction of $66,897.60. Following the transaction, the chief executive officer now directly owns 971,018 shares in the company, valued at approximately $7,030,170.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 11.33% of the company’s stock.
Hedge Funds Weigh In On Concert Pharmaceuticals
Institutional investors have recently modified their holdings of the company. International Biotechnology Trust PLC acquired a new position in shares of Concert Pharmaceuticals during the second quarter worth approximately $620,000. Black Diamond Financial LLC raised its position in Concert Pharmaceuticals by 50.0% in the 2nd quarter. Black Diamond Financial LLC now owns 69,000 shares of the biotechnology company’s stock valued at $290,000 after buying an additional 23,000 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Concert Pharmaceuticals by 1,618.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 548,843 shares of the biotechnology company’s stock valued at $2,311,000 after buying an additional 516,912 shares during the last quarter. Franklin Resources Inc. purchased a new stake in Concert Pharmaceuticals in the 2nd quarter valued at $295,000. Finally, Ensign Peak Advisors Inc purchased a new stake in Concert Pharmaceuticals in the 2nd quarter valued at $372,000. 70.63% of the stock is owned by institutional investors and hedge funds.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders.
- Get a free copy of the StockNews.com research report on Concert Pharmaceuticals (CNCE)
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.